Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01696734 · ClinicalTrials.gov registry record · Phase 3

Domperidone in Treating Patients With Gastrointestinal Disorders

A Phase 3 study of Gastroparesis and Gastroesophageal Reflux Disease, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 3
Development phase
200
Enrollment target
1
Study location

NCT01696734 is a Phase 3 study of Gastroparesis and Gastroesophageal Reflux Disease that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants, below the 298-participant average among 44 other Gastroparesis trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01696734, a Phase 3 study of Gastroparesis and Gastroesophageal Reflux Disease, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 3
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.

Interventions

  • OTHER Questionnaire Administration
  • DRUG Domperidone

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2012-10-23
Est. Completion 2027-10-31
Phase Phase 3

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT01696734

The ClinicalTrials.gov registry entry for NCT01696734 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 298-participant average among 44 other Gastroparesis trials with a reported enrollment target (33% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire Administration is the first listed.

NCT01696734 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01696734 about?

NCT01696734 is a clinical study titled "Domperidone in Treating Patients With Gastrointestinal Disorders". This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its...

What is the current status of trial NCT01696734?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2012-10-23. Estimated completion is 2027-10-31.

What conditions does trial NCT01696734 study?

This clinical trial studies the following conditions: Gastroparesis, Gastroesophageal Reflux Disease, Dyspepsia, Heartburn, Nausea and Vomiting.

What interventions are being tested in trial NCT01696734?

The interventions under investigation include: Questionnaire Administration (OTHER), Domperidone (DRUG).

Who is sponsoring clinical trial NCT01696734?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01696734 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.